Summary. -Protein phosphatase 1, regulatory subunit 15A (PPP1R15A), also known as growth arrest and DNA damage-inducible protein GADD34, plays a vital role in promoting cell death and the unfolded protein response (UPR). In order to explore whether the SNP (rs611251) of PPP1R15A gene has a role in diff erent types of Epstein-Barr virus (EBV)-associated tumors, we detected the PPP1R15A gene rs611251 polymorphism in 195 cases of EBV positive tumors (93 lymphomas, 48 gastric carcinomas, 54 nasopharyngeal carcinomas), 208 cases of EBV-negative tumors (136 gastric carcinoma, 19 nasopharyngeal carcinomas, 53 lymphomas) and 113 peripheral blood samples from healthy individuals. Compared with normal controls, the wild type TT and allele T of rs611251 showed higher frequency in gastric carcinoma (GCs), nasopharyngeal carcinomas (NPCs) and lymphomas. However, there was no signifi cant diff erence between EBV-associated gastric (EBVaGC) and EBVnGC, EBV-positive NPCs and EBV-negative NPCs, EBV-related lymphomas and EBV-negative lymphomas in rs611251 of PPP1R15A. In conclusion, the PPP1R15A rs611251 polymorphism was signifi cantly related to three kinds of tumors. Nevertheless, EBV has no obvious eff ect on PPP1R15A rs611251 polymorphism of NPC, GC and lymphoma. What's more, the genotype TT and allele T could be risk factors for NPC, GC and lymphoma. Our study explores the relationship between PPP1R15A gene polymorphism (rs611251) and EBV-associated tumors for the fi rst time. PPP1R15A gene SNP (rs611251) have association with multiple tumor types, which may provide some new clues to the detection and treatment of tumors.
Introduction
Epstein-Barr virus (EBV) was the fi rst human virus to be directly implicated in carcinogenesis and is a prevalent gamma-herpes virus infecting more than 90% of the human population worldwide. Although EBV coexists with most human hosts, persists asymptomatically for life and remains latent in B cells following resolution of infection, it has the potential to be a serious opportunistic pathogen. It has been reported that in some individuals EBV leads to the development of various malignancies, especially several human lymphoid and epithelial tumors, including lymphoma, nasopharyngeal carcinoma (NPC) and gastric cancer (GC) (Th ompson et al., 2004; Akiba et al., 2008) . In the pattern of EBV latent infection, three integral membrane proteins (LMP1, LMP2A and LMP2B), two non-coding poly-adenylated RNAs (EBER 1 and 2) and 6 nuclear proteins (EBNAs 1, 2 3A, 3B, 3C and LP) are expressed. LMP1 is a well-known classical oncoprotein and has been proven to be associated with NPC and lymphoma pathogenesis, whereas it cannot be found in GC (Truong et al., 2009; Chang et al., 2016) . EBNA3C is essential for proliferation of EBV-infected B-lymphocytes as an EBVencoded nuclear protein.
PPP1R15A is a member of a group of genes whose transcript levels are increased following stressful growth arrest conditions and treatment with DNA-damaging agents. Th is gene induces growth arrest and the expression of DNA damage-inducible protein 34 (GADD34). It has been reported that the activation of GADD34 is a downstream event in apoptotic signaling pathways and may directly contribute to the apoptotic process (Hollander et al., 2001; . However, more recent work has demonstrated that expression of GADD34 promoted growth of lung carcinoma and revealed the exact immunological mechanisms . Th e reduction of GADD34 expression signifi cantly suppressed tumor, resulted in decreased accumulation of myeloid-derived suppressor cells (MDSCs) and T-cells. Th e inhibition of GADD34 also reduced secretion of vascular epithelial growth factor α and transforming growth factor β by MDSCs (Isobe et al., 2016) . It has been observed that EBNA3C can interact with GADD34 to counteract the unfolded protein response, which maintains protein homeostasis by governing the processing capacity of the endoplasmic reticulum (ER) to manage ER client loads (Garrido et al., 2009; Young et al., 2016) . Moreover, it has been reported that GADD34 expression enhanced colorectal cancer (CRC) tumorigenesis . Th e SNP (rs557806) of PPP1R15A gene may improve the identifi cation of metastatic colorectal cancer (mCRC) patients sensitive to bevacizumab regimens and improve personalized treatment of mCRC. Th is SNP might be a candidate biomarker on the basis of correlations with clinicopathologic parameters and clinical responses (Roh et al., 2016) .
SNPs have been the focus of much interest and debate in recent years regarding their possible role in the development of various types of cancer (Wu et al., 2013) . It is widely accepted that the signifi cant SNPs can be used as biomarkers for diagnosis and to evaluate the risk and prognosis of some diseases including cancers (Pipan et al., 2015; Xu et al., 2015; Kuang et al., 2016) . However, there is little information available in literature about PPP1R15A gene polymorphism. Th e role of PPP1R15A in EBV-associated carcinomas including GC, NPC and lymphomas has not yet been explored. Th e purpose of this study was to assess the polymorphism (rs611251) of PPP1R15A in GC, NPC and lymphomas in Northern China. Furthermore, an association between the PPP1R15A gene polymorphism (rs611251) and susceptibility to Epstein-Barr virus-associated carcinomas was also explored.
Materials and Methods
Specimens. Th is study was approved by the Medical Ethical Committee of the Medical College, Qingdao University. All patients participating in the present study gave informed consents for the use of tissue samples for research. We collected 146 lymphoma tissues, 184 GC tissues and 73 NPC tissues from the Department of Pathology of the Affi liated Hospital of Qingdao University, which is located in Shandong Province of northern China. None of the patients received chemotherapy, radiotherapy or hormone therapy. One hundred and thirteen peripheral blood samples, which were collected from Qingdao Blood Center, were classifi ed as a control group. Th e individuals in this group have no history of cancer and did not receive any medications. EBV-associated tumors were confi rmed with EBV-encoded small RNA (EBER) 1 in situ hybridization, as described previously (Tokunaga et al., 1993) .
DNA extraction. DNA was extracted from fresh tumor tissues and whole-blood samples using the traditional phenol-chloroform method with proteinase K digestion (Wallace, 1987) . Th e QIAamp DNA FFPE Tissue Kit (QIAGEN GmbH, Hilden, Germany) was used to extract DNA from paraffi n-embedded carcinoma tissues. Th e extracted DNA was stored at -20˚C until the experiment was carried out.
Methods of genotyping and statistical analysis. SNPs were genotyped using Sequenom Mass-ARRAY technology, and genotypic frequencies in controls were tested in accord with Hardy-Weinberg equilibrium using Fisher's exact test (χ 2 = 0.32, P >0.05). Statistical analysis was conducted using SPSS 18.0 statistical soft ware (SPSS, Chicago, IL, USA). Th e Chi-square test was used to compare diff erences between various types of tumor cases and controls regarding genotype and allele frequencies of rs611251 in each group. Th e odds ratio (OR) and 95% confi dence intervals (CI) were calculated with unconditional logistic regression analysis. Th e odds ratio (OR) and P values were used to assess the correlation between genotype and the risk among diff erent types of tumor in present research. A twosided P-value <0.05 was defi ned as a signifi cant threshold.
Results

Th e distribution of genotype and allelic frequency of PPP1R15A (rs611251) in GC
Th e PPP1R15A gene SNP (rs611251) was successfully genotyped and analyzed in 184 GC specimens including 48 EBVaGCs and 136 EBVnGCs. Th e results showed that the frequency of genotype TT and allele T of rs611251 was signifi cantly higher in GC cases than in controls. Furthermore, the allele C showed a decreased risk of GCs. Th e genotypes and variants of PPP1R15A gene in the GCs are listed in Table 1 . To explore the relationship between EBV infection and PPP1R15A gene polymorphism (rs611251) in GC development, we analyzed diff erences in the PPP1R15A genotype (rs611251) distribution between EBVaGC and EBVnGC. However, there was no signifi cant diff erence between them (Table 2) . Compared with controls, the genotype TT and allele T frequency of rs611251 was signifi cantly higher in EBVnGCs. Furthermore, the TC genotype and allele C showed a decreased risk of EBVnGCs. No signifi cant diff erence was found between EBVaGCs and control (Table 3) .
Th e distribution of genotype and allelic frequency of PPP1R15A (rs611251) in NPC
Th e PPP1R15A gene SNP (rs611251) was successfully genotyped and analyzed in 73 NPC specimens including 54 EBV-positive NPCs and 19 EBV-negative NPCs. Th e frequency of genotype TT and allele T was signifi cantly higher in EBV-positive NPCs and EBV-negative NPCs than that in controls. Furthermore, the genotype TC and allele C showed a decreased risk for NPCs. Th e genotypes and variants of latent genes in the NPCs are listed in Table 4 . However, no signifi cant diff erence was found between EBV-positive NPCs and EBV-negative NPCs (Table 5) .
Th e distribution of genotypic and allelic frequency of PPP1R15A (rs611251) in lymphomas
Th e PPP1R15A gene SNP (rs611251) was successfully genotyped and analyzed in 146 lymphoma specimens including 93 EBV-positive lymphomas and 53 EBV-negative lymphomas. Th e results showed that TT genotype and allele T frequency of rs611251 was signifi cantly higher in EBV-positive lymphomas and EBV-negative lymphomas than that in controls. Furthermore, the TC genotype and allele C showed a decreased risk of two groups. Th e genotypes and variants of PPP1R15A genes in the lymphomas are listed in Table 6 . Moreover, no signifi cant diff erence was found between EBV-positive lymphomas and EBV-negative lymphomas (Table 7) .
Discussion
In the present study, we fi rst investigated PPP1R15A gene polymorphism (rs611251) in lymphomas, NPCs and GC specimens. Th e rs611251 is located at the genomic position of 48873829 on chromosome 19. Th e mutation of this site is T-C nucleotide mutation, which leads to Val-Ala mutation. We found that the distribution of wild genotype TT and allele T showed a higher frequency in lymphomas, NPCs and GC samples, which may be a risk factor for these tumors. Th e allele C showed a decreased risk of lymphomas, NPCs and GC samples than that in controls. Consequently, the mutation of this site may be a protective factor for NPC, GC and lymphoma. However, little is known about the relationship between SNP (rs611251) with EBV-associated tumors.
It is well known that NPC is closely related to EBV infection. Expression of the oncogene LMP1 has been associated with NPC pathogenesis (Baichwal et al., 1988) . In the present study, we found that the distribution of genotype TT and allele T showed a higher frequency both in EBV-positive NPCs and EBV-negative NPCs compared with the normal controls. Th e allele C also showed a decreased risk of EBV-positive NPCs and EBV-negative NPCs. It indicated that genotype TT and allele T may be a risk factor for NPCs.
GC is a heterogeneous disease that is largely infl uenced by H. pylori infection, environmental factors and genetic susceptibility. Epidemiological studies have shown that 95% of the adults are infected with EBV infection, though half of the world's population suff ers from H. pylori infection. However, only a small proportion of them progresses to chronic atrophic gastritis and ultimately GC (EBVaGC accounts for 1.3-20.1% in GC and 1-2% H. pylori-infected cases develop GC) (Scholte et al., 2002; Akiba et al., 2008; Uozaki et al., 2008; Lee et al., 2009) . Furthermore, genetic factors may play key important roles in GC development.
Our results showed that the distribution of genotype TT and allele T of PPP1R15A (rs611251) had higher frequency in EBVnGC samples, while EBVaGCs does not refl ect signifi cant diff erence compared with normal controls. Th is diff erence may be related to the aff ection of EBV. However, the statistical analysis indicated that EBVaGCs and EBVnGCs had no signifi cant diff erence with each other, but signifi cant diff erence was found between GCs and controls. Th e genotype TT and allele T of PPP1R15A (rs611251) in GCs may be a risk factor for GCs.
In the present study we found that EBV-positive NPCs have signifi cant diff erence compared with normal controls (P <0.05), but the diff erence between EBVaGCs and normal controls was not signifi cant (P >0.5). NPC and GC were both EBV-associated epithelial carcinomas (Imai et al., 1994) , however, they have diff erent latency types of EBV. Diff erent latency types correlate with specifi c EBV-associated malignancies (Babcock et al., 2000) . It has been reported that oncogene LMP1 inhibits the diff erentiation of human epithelial cells. It is also related to cancer development, growth, invasion, metastasis, and the epithelial-mesenchymal transition (Dawson et al., 1990 , Yoshizaki et al., 2002 . Some authors have reported that LMP1 can be detected in 95.6% of NPC tissues and is associated with NPC pathogenesis, whereas the expression of LMP1 was not found in gastric cancer or in nonneoplastic gastric tissue (Baichwal et al., 1988; Tsang et al., 2003; Truong et al., 2009) . Hence, the diff erent expression of LMP1 maybe a way to explain our results and these fi ndings require further study.
EBV is associated with various lymphoproliferative disorders, such as Burkitt's lymphoma, Hodgkin's lymphoma, T cell lymphoma, B cell lymphoma in immunodefi ciency, and lymphoepithelioma-like carcinoma of the parotid gland (Young et al., 1992; Ambinder et al., 1994) . Our study verifi ed that genotype TT and allele T were also risk factors for lymphoma. It was reported that overexpression of GADD34 enhanced the ability of EBNA3C to co-activate EBNA2, which could activate the LMP1 promoter. EBNA3C is essential to initiate B-cell growth, as well as ongoing B-cell transformation. Moreover, EBNA3C can interact with GADD34 that is upregulated in response to viral infection as well as ER-stress in both nuclear and cytoplasmic compartments and counteracts the unfolded protein response. In addition, the interaction also requires the domination of the HSV-1 ICPγ34.5, which shares homology with GADD34 in the PP1-binding domain (He et al., 1997; Garrido et al., 2009) . However, no signifi cant diff erence was found between three kinds of EBV-associated tumors and corresponding EBV-negative tumors. EBV infection may not play a vital role in the SNP (rs611251) of PPP1R15A. Th e exact mechanism is not yet clear. Further in-depth study and analysis will be necessary under rather more naturalistic conditions to confi rm the relationship between PPP1R15A gene polymorphisms and EBV-associated tumors. Our results are the fi rst to identify that PPP1R15A gene SNP (rs611251) has association with multiple tumor types, which may provide some new clues to the detection and treatment of tumors.
Conclusions
Our present results indicate that the PPP1R15A rs611251 polymorphism was signifi cantly related to three kinds of tumors (NPC, GC and lymphoma) . Th e genotype TT and allele T could be risk factors for NPC, GC and lymphoma. Nevertheless, EBV has no obvious eff ect on PPP1R15A rs611251 polymorphism.
